{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06005740",
            "orgStudyIdInfo": {
                "id": "TORL4500-001"
            },
            "organization": {
                "fullName": "TORL Biotherapeutics, LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer",
            "officialTitle": "A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-phase-first-in-human-study-of-torl-in-patients-with-advanced-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-12",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-04",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-10-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-10-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-15",
            "studyFirstSubmitQcDate": "2023-08-15",
            "studyFirstPostDateStruct": {
                "date": "2023-08-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "TORL Biotherapeutics, LLC",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Translational Research in Oncology",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer"
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor",
                "Hepatocellular Carcinoma"
            ],
            "keywords": [
                "ADC"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 70,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Monotherapy Dose Dose Finding - Part 1",
                    "type": "EXPERIMENTAL",
                    "description": "TORL-4-500 iv once every 3 weeks",
                    "interventionNames": [
                        "Drug: TORL-4-500"
                    ]
                },
                {
                    "label": "Expansion as Monotherapy - Part 2",
                    "type": "EXPERIMENTAL",
                    "description": "TORL-4-500 iv once every 3 weeks",
                    "interventionNames": [
                        "Drug: TORL-4-500"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "TORL-4-500",
                    "description": "antibody drug conjugate",
                    "armGroupLabels": [
                        "Expansion as Monotherapy - Part 2",
                        "Monotherapy Dose Dose Finding - Part 1"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence and severity of adverse events and serious adverse events",
                    "description": "Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Maximum Tolerated Dose (MTD)",
                    "description": "Highest administered dose with \\< 33% participants experiencing dose limiting toxicity (DLT) in the first 6 DLT evaluable participants",
                    "timeFrame": "28 Days"
                },
                {
                    "measure": "Recommended Phase 2 Dose (RP2D)",
                    "description": "Based on the maximum tolerated dose, cumulative safety, and pharmacokinetic data",
                    "timeFrame": "up to 2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Objective Response Rate (ORR)",
                    "description": "Percentage of participants with best response of complete response (CR) or partial response (PR) according to RECIST 1.1",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "Time from CR or PR to objective disease progression or death to any cause",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Progression Free Survival (PFS)",
                    "description": "PFS is defined as the time from the start of the treatment until objective disease progression or death from any cause",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Time to Response (TTR)",
                    "description": "Time from start of treatment to complete response or partial response",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "1 Year Overall Survival (1YOS)",
                    "description": "Proportion of participants alive at 1 year from the start of treatment to death from any cause",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "2 Year Overall Survival (2YOS)",
                    "description": "Proportion of participants alive at 2 years from the start of treatment to death from any cause",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Number of anti-drug antibody (ADA) Positive Participants",
                    "description": "Immunogenicity will be measured by the number of participants that are ADA positive.",
                    "timeFrame": "up to 2 years"
                },
                {
                    "measure": "Maximum Serum Concentration of TORL-4-500 (Cmax)",
                    "description": "PK assessment",
                    "timeFrame": "21 days"
                },
                {
                    "measure": "Minimum Serum Concentration of TORL-4-500 (Cmin)",
                    "description": "PK assessment",
                    "timeFrame": "21 days"
                },
                {
                    "measure": "Maximum Serum Concentration of TORL-4-500 at Steady State (Cmax,ss)",
                    "description": "PK assessment",
                    "timeFrame": "63 days"
                },
                {
                    "measure": "Minimum Serum Concentration of TORL-4-500 at Steady State (Cmin,ss)",
                    "description": "PK assessment",
                    "timeFrame": "63 days"
                },
                {
                    "measure": "Time of Maximum Serum Concentration of TORL-4-500 (Tmax)",
                    "description": "PK assessment",
                    "timeFrame": "21 days"
                },
                {
                    "measure": "Time of Minimum Serum Concentration of TORL-4-500 (Tmin)",
                    "description": "PK Assessment",
                    "timeFrame": "21 days"
                },
                {
                    "measure": "Time of Minimum Serum Concentration of TORL-4-500 at Steady State (Tmin,ss)",
                    "description": "PK Assessment",
                    "timeFrame": "63 days"
                },
                {
                    "measure": "Terminal Half-life (t1/2) of Serum TORL-4-500-ADC",
                    "description": "PK Assessment",
                    "timeFrame": "63 days"
                },
                {
                    "measure": "Area under the Serum Concentration-Time curve from the time of dosing to the last measurable concentration (AUClast) for TORL-1-23",
                    "description": "PK Assessment",
                    "timeFrame": "21 days"
                },
                {
                    "measure": "Area under the Serum Concentration-Time curve from the time of dosing extrapolated to time infinity (AUCinf) for TORL-1-23",
                    "description": "PK Assessment",
                    "timeFrame": "63 days"
                },
                {
                    "measure": "Apparent volume of distribution during the terminal phase (Vz) of TORL-4-500",
                    "description": "PK Assessment",
                    "timeFrame": "63 days"
                },
                {
                    "measure": "Clearance (CL) of TORL-4-500",
                    "description": "PK Assessment",
                    "timeFrame": "63 days"
                },
                {
                    "measure": "Accumulation ratio (Rac) of TORL-4-500",
                    "description": "PK Assessment",
                    "timeFrame": "63 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Advanced solid tumor\n* Measurable disease, per RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Has not recovered \\[recovery is defined as NCI CTCAE, version 5.0, grade \u22641\\] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements\n* Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-4-500\n* Progressive or symptomatic brain metastases\n* Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection\n* History of significant cardiac disease\n* History of myelodysplastic syndrome (MDS) or AML\n* History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. A history of other malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate cancer with a Gleason score less than or equal to 6, are also not excluded\n* If female, is pregnant or breastfeeding",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Stephen Letrent, PharmD, PhD",
                    "role": "CONTACT",
                    "phone": "858-342-6652",
                    "email": "stephen.letrent@torlbio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Stephen Letrent, PharmD, PhD",
                    "affiliation": "TORL Biotherapeutics, LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCLA - JCCC Clinical Research Unit",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lee Rosen, MD",
                            "role": "CONTACT",
                            "phone": "310-829-5471"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006528",
                    "term": "Carcinoma, Hepatocellular"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008113",
                    "term": "Liver Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M9613",
                    "name": "Carcinoma, Hepatocellular",
                    "asFound": "Hepatocellular Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11113",
                    "name": "Liver Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}